Applications of Cbz-S-Phenyl-L-Cysteine in Industrial Manufacturing

Cbz-S-Phenyl-L-Cysteine, a protected amino acid, serves as a critical intermediate in advanced pharmaceutical, peptide, and specialty chemical manufacturing. Our production supports multiple industrial sectors requiring precise quality and consistent material performance.

1. Peptide API Synthesis

This compound functions as a chiral building block in the solid-phase or solution-phase synthesis of complex peptide active pharmaceutical ingredients. It enables the site-specific incorporation of a cysteine residue with preserved stereochemistry. Manufacturers rely on its reactivity and protection profile to facilitate stepwise peptide coupling, minimizing racemization and unwanted byproduct formation during scale-up. Its use streamlines purification and supports compliance with regulatory expectations for peptide-based therapeutics.

Industry compliance standards

• ICH Q7 – Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
• USP/NF and European Pharmacopoeia standards for peptide APIs
• cGMP FDA 21 CFR Parts 210/211 for pharmaceutical production
• ISO 9001:2015 for quality management systems

Typical usage ratio

• Equimolar to target cysteine position; adjusted 1:1.05–1.2x to compensate for coupling losses, based on batch process control and peptide length

Downstream process integration

• Used at protected cysteine coupling stage on resin or solution
• Removed protecting group prior to final deprotection steps
• Monitored by HPLC and chiral analysis in intermediate QC

Final product types

• Custom therapeutic peptides (e.g., GLP-1 analogues, peptide antibiotics, synthetic hormones)
• Peptide drug substances for parenteral and oral formulations

2. Pharmaceutical Intermediate for Chiral Molecule Synthesis

It plays a vital role as a stereochemically defined intermediate in the preparation of enantiopure chiral pharmaceuticals. Chemical process engineers utilize its distinct S-configuration and Cbz protection to build up molecular complexity with controlled stereo-integrity. The material acts as a platform for further functional group transformation, coupling, and deprotection as mandated by API synthesis flowsheets.

Industry compliance standards

• ICH Q11 – Development and Manufacturing of Drug Substances
• FDA Guidance for Industry: QbD for APIs
• REACH (EC 1907/2006) chemical safety reporting for intermediates
• ISO 14001:2015 for environmental management (where applicable)

Typical usage ratio

• Stoichiometry determined by target chiral center incorporation; usually 0.8–1.1 molar equivalents per transformation step, with minor excess if purification steps require loss compensation

Downstream process integration

• Introduced during chiral auxiliary or side-chain synthesis steps
• Deprotected and functionalized under mild conditions to retain chirality
• Used as a core chiral source in asymmetric synthesis benches

Final product types

• Small molecule APIs with thioether, amide, or carboxyl functionality
• Chiral industrial intermediates for custom-ordered pharmaceutical projects

3. Protected Amino Acid for Custom Peptide Reagent Manufacturing

Chemical reagent manufacturers select this protected cysteine derivative to prepare custom peptide reagents for in vitro diagnostics, biochemical studies, and reference standards. Its defined chemical structure ensures compatibility with automated peptide synthesizers and robustness in multi-step labeling protocols. Clean removal of Cbz and S-phenyl protecting groups ensures downstream product purity matching research-grade specifications required by quality control laboratories and IVD kit assemblers.

Industry compliance standards

• ISO 13485:2016 for IVD and medical device laboratories
• ISO/IEC 17025 for accredited testing reagent manufacture
• REACH SVHC and Annex XVII compliance for supplied research chemicals
• Internal QC validated methods (HPLC, LC-MS, NMR analytical standards)

Typical usage ratio

• Batch preparations utilize 1.0–1.05 equivalents per peptide coupling; excess beyond this only for scale-up validation runs

Downstream process integration

• Loaded as the cysteine residue source during SPPS cycles
• Compatibilized with other protected amino acids in cartridge and resin feed systems
• Integrated with in-line deprotection units prior to HPLC fractionation

Final product types

• Synthetic peptide calibrators for diagnostic test kits
• Peptide mapping standards for proteomics research labs

4. Building Block for Custom Peptide Conjugates in Biotech

This chemical intermediate supports the creation of peptide conjugates bearing functional markers or biotin, which are used for affinity purification columns or molecular probes. Its stable protection groups allow manufacturers to conduct multi-step conjugation and selective labeling in controlled conditions. After sequential deprotection and side chain derivatization, downstream bioconjugation teams can link target analytes or reporter tags to free thiol groups, allowing precise lot-to-lot consistency and functional capability demonstration in customer biotech workflows.

Industry compliance standards

• 21 CFR Part 820 – Quality System Regulation (biotech reagents)
• ISO 9001:2015 for manufacturing controls
• GLP for documentation in research-use-only (RUO) production lines
• REACH registration for specialty biotech chemicals

Typical usage ratio

• Used at 1 equivalent per labeling site in peptide sequence; for conjugate synthesis, up to 1.2 equivalents to assure complete tagging, adjusted based on conjugation efficiency analytics

Downstream process integration

• Employed at the early derivatization phase for protected peptide assembly
• Deprotection performed prior to label or biotin attachment
• Conjugate product purified on preparative HPLC and tested by MS

Final product types

• Biotinylated peptides for streptavidin-coated purification platforms
• Fluorescently labeled peptide markers and probes
• Enzyme conjugated peptide substrates for bioassays

5. Raw Material for Specialty Fine Chemicals and Chiral Ligand Synthesis

Synthetic laboratories use this S-phenyl protected cysteine derivative in the construction of chiral ligands and fine chemical intermediates. Its structure provides a reliable source of sulfur- and aryl-functionalized chiral elements, necessary for downstream catalytic or stereoselective reactions. The carefully controlled protection groups prevent side reactions during multi-step organic syntheses, and are selectively removed under defined conditions without affecting desired product purity or yield.

Industry compliance standards

• REACH and CLP (EC 1272/2008) compliance for raw materials in EU
• ISO 9001:2015 for specialty chemical manufacturing
• SHE (Safety, Health, Environmental) audits for process safety
• Customer-specific specification agreements (COA, MSDS, batch traceability)

Typical usage ratio

• Dosage based on projected chiral center introduction per synthetic sequence, typically 0.95–1.1 equivalents; ratios further specified by the complexity of ligand or intermediate being produced

Downstream process integration

• Fed into multi-step organic synthesis for initial chiral scaffold formation
• Protection groups cleaved in late-stage process steps to liberate functional residues
• Material tracked and traced for each batch by analytical QC (NMR, IR, MP)

Final product types

• Chiral ligands for asymmetric catalysis
• Sulfur-containing fine chemicals used in flavor/fragrance precursor development
• Key intermediate building blocks for further specialty synthesis